The efficacy of donafenib mesylate tablets is to inhibit the propagation of tumor cells and tumor angiogenesis. This drug is a new type of targeted drug, belonging to multikinase inhibitor, with dual anti-tumor effect, not only can inhibit the generation and reproduction of tumor cells, but also can block the binding of vascular endothelial growth factor receptor and PDGFR, inhibit angiogenesis to block the nutrient supply, so as to play a role in shrinking the tumor and controlling the disease. This drug is mainly used for patients with inoperable hepatocellular carcinoma and advanced renal carcinoma, during the period of using this drug, adverse reactions such as diarrhea, skin rash and mouth ulcer may occur, in addition, pregnant women, infants and young children, and allergic people need to be cautious about using it.